HitGen Inc. (SHA:688222)

China flag China · Delayed Price · Currency is CNY
27.41
-2.22 (-7.49%)
At close: Jun 1, 2026
Market Cap11.84B +95.6%
Revenue (ttm)579.37M +35.9%
Net Income127.23M +93.7%
EPS0.31 +79.5%
Shares Out 399.44M
PE Ratio95.47
Forward PE87.15
Dividend0.06 (0.20%)
Ex-Dividend Daten/a
Volume18,791,540
Open29.58
Previous Close29.63
Day's Range27.41 - 29.66
52-Week Range14.96 - 42.98
Beta0.58
AnalystsStrong Buy
Price Target31.60 (+15.29%)
Earnings DateAug 28, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 492
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688222
Full Company Profile

Financial Performance

In 2025, HitGen's revenue was 525.57 million, an increase of 23.09% compared to the previous year's 426.99 million. Earnings were 114.02 million, an increase of 122.01%.

Financial Statements